Novel Radiolabeled ADC Could Improve Outcomes in High-Risk AML
Older patients with active, relapsed, or refractory acute myeloid leukemia have a low survival rate, very poor risk assessments, and limited therapeutic options, with conventional care consisting primarily of salvage chemotherapy.
Read full article (External website)
Leave a Reply
Want to join the discussion?Feel free to contribute!